These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25465821)

  • 21. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
    Patel S; Veltri K
    J Pharm Pract; 2017 Oct; 30(5):541-548. PubMed ID: 27194070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
    Pugliese NR; Masi S; Taddei S
    Heart Fail Rev; 2020 Jan; 25(1):31-42. PubMed ID: 31512149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.
    Oliveros E; Oni ET; Shahzad A; Kluger AY; Lo KB; Rangaswami J; McCullough PA
    Cardiorenal Med; 2020; 10(2):69-84. PubMed ID: 32062648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction.
    Renew JR; Cyrille N; Elyahu AY; Ramakrishna H
    J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1500-1506. PubMed ID: 29373183
    [No Abstract]   [Full Text] [Related]  

  • 27. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.
    Lu BN; Davis LE
    JAAPA; 2018 Jul; 31(7):35-37. PubMed ID: 29957605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
    Luo N; Fonarow GC; Lippmann SJ; Mi X; Heidenreich PA; Yancy CW; Greiner MA; Hammill BG; Hardy NC; Turner SJ; Laskey WK; Curtis LH; Hernandez AF; Mentz RJ; O'Brien EC
    JACC Heart Fail; 2017 Apr; 5(4):305-309. PubMed ID: 28359417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Change in renal function associated with drug treatment in heart failure: national guidance.
    Clark AL; Kalra PR; Petrie MC; Mark PB; Tomlinson LA; Tomson CR
    Heart; 2019 Jun; 105(12):904-910. PubMed ID: 31118203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.
    Valluri A; Struthers AD; Lang CC
    Curr Heart Fail Rep; 2014 Mar; 11(1):31-9. PubMed ID: 24234398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do beta-blockers and inhibitors of the renin-angiotensin aldosterone system improve outcomes in patients with heart failure and left ventricular ejection fraction >40%?
    Lumbers RT; Martin N; Manoharan K; Thomas J; Davies LC
    Heart; 2019 Oct; 105(20):1533-1535. PubMed ID: 31345952
    [No Abstract]   [Full Text] [Related]  

  • 34. Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.
    Khatib R; Joseph P; Briel M; Yusuf S; Healey J
    Int J Cardiol; 2013 Apr; 165(1):17-24. PubMed ID: 22421406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novelties in Therapy of Chronic Heart Failure.
    Doimo S; Pavan D
    Heart Fail Clin; 2021 Apr; 17(2):255-262. PubMed ID: 33673949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials].
    Filardi PP; Paolillo S; Indolfi C; Agostoni P; Basso C; Barillà F; Correale M; Curcio A; Mancone M; Merlo M; Metra M; Muscoli S; Nodari S; Palazzuoli A; Pedrinelli R; Pontremoli R; Senni M; Volpe M; Sinagra G
    G Ital Cardiol (Rome); 2022 Mar; 23(3):217-228. PubMed ID: 35343504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

  • 39. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
    Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.